68 related articles for article (PubMed ID: 12017336)
1. Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study.
Coley HM; Sargent JM; Williamson CJ; Titley J; Scheper RJ; Gregson SE; Elgie AW; Lewandowicz GM; Taylor CG
Anticancer Res; 2002; 22(1A):69-74. PubMed ID: 12017336
[TBL] [Abstract][Full Text] [Related]
2. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
5. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
7. Overcoming MDR by ultrasound-induced hyperthermia and P-glycoprotein modulation.
Liu Y; Lillehei K; Cobb WN; Christians U; Ng KY
Biochem Biophys Res Commun; 2001 Nov; 289(1):62-8. PubMed ID: 11708777
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer.
Krasznai ZT; Friedländer E; Nagy A; Szabó G; Vereb G; Goda K; Hernádi Z
Anticancer Res; 2005; 25(2A):1187-92. PubMed ID: 15868961
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
Shen F; Chu S; Bence AK; Bailey B; Xue X; Erickson PA; Montrose MH; Beck WT; Erickson LC
J Pharmacol Exp Ther; 2008 Jan; 324(1):95-102. PubMed ID: 17947497
[TBL] [Abstract][Full Text] [Related]
10. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
Shen X; Chen G; Zhu G; Fong WF
Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
[TBL] [Abstract][Full Text] [Related]
11. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Perry WL; Shepard RL; Sampath J; Yaden B; Chin WW; Iversen PW; Jin S; Lesoon A; O'Brien KA; Peek VL; Rolfe M; Shyjan A; Tighe M; Williamson M; Krishnan V; Moore RE; Dantzig AH
Cancer Res; 2005 Aug; 65(15):6593-600. PubMed ID: 16061639
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells.
Ma S; Jia R; Li D; Shen B
Biomed Res Int; 2015; 2015():453986. PubMed ID: 26558272
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Chen LM; Liang YJ; Zhang X; Su XD; Dai CL; Wang FP; Yan YY; Tao LY; Fu LW
Anticancer Res; 2009 Nov; 29(11):4597-604. PubMed ID: 20032409
[TBL] [Abstract][Full Text] [Related]
16. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
17. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
18. Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.
Fridborg H; Jonsson B; Nygren P; Csoka K; Nilsson K; Oberg G; Kristensen J; Bergh J; Tholander B; Olsen L
Br J Cancer; 1994 Jul; 70(1):11-7. PubMed ID: 8018519
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
20. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
